CHI Announces its Fourth Annual Novel Vaccines: Adjuvants and Delivery Systems Conference

April 27, 2012 - PRLog -- NEEDHAM, MASS. – April 27, 2012 – Adjuvants and Novel Delivery Systems are widely accepted as key to creating more efficacious vaccines with improved methods for storage and delivery. Join us August 15-16, 2012 in Cambridge, MA as this leading vaccine meeting addresses the ongoing achievements of creating the next generation of vaccines, including toll-like receptor technology and DNA vaccines. Though lack of FDA approval for new adjuvants presents a major hurdle, researchers continue to delineate adjuvants’ mode of action in the quest to improve vaccines for human use. In the Adjuvants & Delivery Systems meeting, vaccine leaders will discuss their innovative work that is creating a new era of advanced vaccines. For more information, please visit http://www.ImVacS.com.

Speakers Include:  (partial listing)

- Bali Pulendran, Ph.D., Professor, Pathology and Laboratory Medicine, Emory University School of Medicine

- Inna G. Ovsyannikova, Ph.D., Associate Professor, Medicine, Mayo Vaccine Research Group, Mayo Clinic College of Medicine

- Fabio Bagnoli, Ph.D., Project Leader, Novartis Vaccines & Diagnostics

- John W. Shiver, Ph.D., Vice President, Vaccines Discovery, Merck & Co., Inc.

- Rebecca Sheets, Ph.D., Vaccine Scientific and Regulatory Specialist, USPHS, NIH/NIAID

- John Amery, Ph.D., Senior Principal Scientist, Analytical Research and Development, Pfizer BioTherapeutics Pharmaceutical Sciences

- Andrew Geall, Ph.D., RNA Vaccine Platform Leader, Novartis Vaccines and Diagnostics

- Nicholas M. Valiante, Ph.D., Head, Immunology, Novartis Vaccines & Diagnostics, Inc
.
- Ross Kedl, Ph.D., Associate Professor, Associate Graduate Program Director, Department of Immunology, University of Colorado Denver

- Sudhir Agrawal, D.Phil., CEO, Idera Pharmaceuticals

- Ofer Levy, M.D., Ph.D., Principal Investigator, Medicine/Infectious Diseases, Children’s Hospital Boston

- Murali Bilikallahalli, Ph.D., Vaccines Formulation and Development, MedImmune LLC

- Andrew Bacon, Principal Scientist and Head, Liposome-Based Vaccines Group, R&D Laboratories, Xenetic Biosciences plc

- Darrell J. Irvine, Ph.D., Associate Professor, Materials Science & Engineering, Biological Engineering, Massachusetts Institute of Technology

- David E. Anderson, Ph.D., Vice President, Research, VBI Vaccines

- Ramadevi Raghunandan, Ph.D., Manager, Pre-Clinical Immunology, Novavax

- Takashi Kishimoto, Ph.D., CSO, Selecta Biosciences

- Bjarne Bogen, Ph.D., Professor of Medicine, Immunology, University of Oslo

- Ali Fattom, Ph.D., Senior Vice President, Vaccine Research & Development, NanoBio Corp.

For more information, please visit http://www.imvacs.com

Register by May 18 to save up to $370!

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
Tracey Fielding
Marketing Manager
Cambridge Healthtech Institute
tfielding@healthtech.com